GoofGoof
Premium Member
Good summary. The 2 logistical things that could delay the process of getting enough people vaccinated are the ultra cold storage limitation and the fact that the vaccines require 2 doses usually 30 days apart. On the cold storage side I think it just makes it that much more difficult to distribute to medical providers. You would probably need large numbers of people to go to a centralized location vs sending it to every doctors office and CVS. The 2 dose thing just cuts the number of people in half. For example if the US government buys 100M doses that only vaccinated 50M people since everyone needs 2.Where's the best place to live? Oh wait. That's off topic.
Anyhoo... reading about the status of various vaccines have left me confused as to which vaccines are which and where they are in development and who's saying what about how far along they are. So, I made an outline...
Monderna/NIH
Type: mRNA (requires ultra-cold storage and 2 doses)Warp Speed: $2.5B, for 100M dosesPhase 3: Started Jul 27, 30K people, enrollment completes in SeptemberEarliest according to CDC: “Vaccine B” – local health departments, prepare for Oct (just in case, if all goes very well). Late Oct or Nov. 1M doses by Oct, 10M by Nov, 15M by Dec.Earliest according to manufacturer: no estimate given
Biontech/Pfizer/Fosun
Type: mRNA (requires ultra-cold storage and 2 doses)Phase 3: Started Jul 27, 30K peopleWarp Speed: $1.9B for 100M doses (by Dec?)Earliest according to CDC: “Vaccine A” – health departments, prepare for Oct (just in case, if all goes very well). Late Oct or Nov. 2M doses by end of Oct, 10-20M doses by Nov, 20-30M dosed by Dec.Earliest according to manufacturer: Regulatory review in Oct.
AstraZeneca/Oxford
Type: altered chimp adenovirusWarp Speed: $1.2BPhase 3: in progress, recently startedEarliest according to CDC: Doses can be delivered by Oct.Earliest according to manufacturer: Doses available by the end of 2020.
Phase 3:
Final phase of trials. A large number of people are given either the vaccine or placebo, double blindWait to see if there are negative reactions to the vaccine. If there are, vaccine is scrubbed.Wait to see how much more the vaccinated group is protected compared to the placebo. To be effective, it should be 50% more protected.If early results show extraordinarily good results, then this Phase can end early, because it would be unethical to leave those who received the placebo to be unprotected by an effective vaccine – this is what leads to an “October vaccine,” which, is only a result of extraordinarily good results.An independent review board evaluates the effectiveness. The FDA will not approve (or, is not supposed to approve) a vaccine without the board's go-ahead.In addition to governmental approval (or "fast-tracking"), the manufacturers themselves can decide not to release the vaccine until what they consider are appropriate evaluations are made.
In short, as Dr. Fauci has said, an October vaccine is not impossible, just very unlikely.